Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70-targeted CAR-T in Advanced Solid Tumors
NCT05468190Phase 1Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD70 CAR-T cells in renal cell carcinoma (RCC), ovarian cancer, Cervical Cancer (CC) and 1 more (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse events after CD70 CAR-T cells infusion at 28 days and Maximum Tolerated Dose of CD70 CAR-T cells at 28 days. Status: unknown.
02
Drugs
CD70 CAR-T cells
03
Conditions
renal cell carcinoma (RCC)ovarian cancerCervical Cancer (CC)solid tumor
Beyond the preview
Go deeper on NCT05468190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468190.